Management of oral mucositis induced by chemotherapy and radiotherapy: An update

Quintessence International

Volumn 35, Issue 2, 2004, Pages 129-136

  Vélez, Inés ^a   Tamara, Luis A ^b   Mintz, Sheldon ^a,c,d  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b New Hanover Medical Center   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemotherapy; Mucositis; Oral; Radiotherapy

Indexed keywords

ADENOSINE DERIVATIVE; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CAMPTOTHECIN; CANNABINOID; CHLORMETHINE DERIVATIVE; EPIPODOPHYLLOTOXIN DERIVATIVE; FENTANYL; FOLIC ACID DERIVATIVE; GLUTAMINE; GLUTATHIONE; IMMUNOMODULATING AGENT; IRIDIUM; LYSOFYLLINE; MORPHINE; NITROSOUREA DERIVATIVE; PLATINUM DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPROTECTIVE AGENT; RECOMBINANT GROWTH FACTOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BEAM THERAPY; BRACHYTHERAPY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONSULTATION; CRYOTHERAPY; GENERAL PRACTITIONER; HEALTH CARE SYSTEM; HUMAN; METAPHASE; MOUTH HYGIENE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; ONCOLOGY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RADIOIMMUNOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; CELL DEATH; CRANIAL IRRADIATION; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH MUCOSA; STOMATITIS;

EID: 0842333925     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 1993;9:185-195.
2. Pazdur R, Coia L, Hoskins WJ, Wagrnan L. Cancer Management: A Multidisciplinary Approach, ed 5. Melville, NY: PRR, 2001:754,805,810-813.
3. Chao KSC, Perez CA, Brady LW. Radiation Oncology. Management Decisions, ed 2. Philadelphia: Lippincott Williams & Wilkins, 2002:1.
4. Muray IPC, Ell PJ. Nuclear Medicine. Clinical Diagnosis and Treatment, ed 1. New York: Churchill Livingstone, 1995:865-876.
5. Khalkhali I, Maublant JC, Goldsmith SJ. Nuclear Oncology. Diagnosis & Therapy. Philadelphia: Lippincott Williams & Wilkins, 2001:3-12,60-68.
6. Dorr W, Hamilton CS, Boyd T, Reed B, Denham JW. Radiation induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002;52: 911-917.
7. Neville BW, Douglas DD, Allen CM, Bouquot JE. Oral and Maxillofacial Pathology, ed 2. Philadelphia: Saunders, 2002:262.
8. Little JW, Falace DA, Miller CS, Rhodus NL. Dental Management of the Medically Compromised Patient, ed 5. St Louis: Mosby, 1997:539.
9. Mills EED. The modifying effect of beta carotene on radiation and chemotherapy induced oral mucositis. Brit J Cancer 1988;57:416-417.
10. Wadleigh RG. Vitamin E and chemotherapy induced oral mucositis. Amer J Med 1992;92:481-482.
11. Bronchud MH, Howell A, Crowther D. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with breast and ovarian cancer. Br J Cancer 1989;60:121-125.
12. Furst P, Albers S, Stehele P. Evidence for a nutritional need for glutamine in catabolic patients. Kidney Int 1989;36: S287-S292.
13. Yoshida S. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg 1998;227:485-491.
14. Lapeyre M, Charra-Brunaud C, Kaminsky MC, et al. Management of mucositis following radiotherapy for head and neck cancers. Cancer Radiother 2001;5(suppl 1):121s-130s.
15. Klimberg VS. How glutamine protects the gut during irradiation. ICCN 1996;3:21.
16. Skubitz KM, Anderson PM. Oral glutamine to prevent chemotherapy stomatitis: A pilot study. J Lab Clin Med 1996;127:223-228.
17. Schweitzer EJ, Bass BL, Johnson LF, Harmon JW. Sucralfate prevents experimental peptic esophagitis in rabbits. Gastroenterology 1985;88(3):611-619.
18. Carl W, Emrich LS. Management of oral mucositis during local radiation and systemic chemotherapy: A study of 98 patients. J Prosthet Dent 1991;66:361-369.
19. Portenoy RK. Cancer pain management. Semin Oncol 1993;20:19-35.
20. Etiz D, Erkal HS, Serin M, et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 2000;36:116-120.
21. Gage TW, Pickett FA. Dental Drug Reference, ed 5. St Louis: Mosby, 2002.
22. Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzidamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001;92:875-885.
23. American Dental Association. Guide to Dental Therapeutics, ed 3. Chicago: American Dental Association, 2003:550.
24. Walker JM, Huang SS. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-135.
25. Jimenez PA, Rampy MA. Keratinocyte growth factor-2 accelerates wound healing in incisional wounds. J Surg Res 1999;81:238-242.
26. Tseng S, Pak G, Washenik K, Pomeranz MK, Shepack L. Rediscovering thalidomide. A review of mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-979.
27. Booth D, Potten CS. Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst Monogr 2001;29:16-20.
28. Dumbrigue HB, Sandow PL, Nguyen KH, Humphreys-Behar MG. Salivary epidermal growth factor levels decrease in patients receiving radiation therapy to the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89:710-716.
29. Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 2000;89(11):2258-2265.
30. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral ulcers in patients with human immunodefficiency virus infection. N Engl J Med 1997;336: 1487-1493.
31. Alexander LN, Wilcox CM. A prospective trial of thalidomide for the treatment of HIV associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 1997;13: 302-304.
32. Keravich DP, Daniels CE. Challenges of thalidomide distribution in a hospital setting. Am J Health Syst Pharm 1999;17:1721-1725.
33. Delanian S, Ball-Mekias S, Lefaix J, et al. Striking regretion of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and α-Tocopherol. J Clin Oncol 1999;17:3283-3290.
34. Schenider SB, Nishimura RD, Zimmerman RP, et al. Filgrastim and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double-blind, placebo-controlled trial. Cytoquines Cell Mol Ther 1999;3:175-178.
35. Nicolatou-Galitis O, Dardoufas K, Markoulatos P, et al. Oral pseudomembranous candidiasis, herpes simplex virus 1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte macrophage colony-stimulating factor (GM-CSF) mouthwash. J Oral Pathol Med 2001;30:471-480.
36. Hensley ML, Schuchter LM, Lindley C, et al. Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-3355.
37. Koukourakis MI. Amifostine in clinical oncology: Current use and future. Anticancer Drugs 2002;13:181-209.
38. Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol 2002;12(1 suppl 1): 97-102.
39. Culy CR, Spencer CM. Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;5:641-684.
40. Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002;12:4-13.
41. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophilactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head and neck cancer. Int J Radiat Oncol Biol Phys 2002; 52:739-747.
42. Mahood DJ, Dose AM, Loprinzi CL. Inhibition of fluoracil induced stomatitis by oral cryotherapy. J Clin Oncol 1991;9:449-452.
43. Vardy J, Wong E, Izard M, Clifford A, Clarke SJ. Life-threatening anaphylactoid reaction to amifostine used with concurrent chemotherapy for nasopharyngeal cancer in a patient with dermatomyositis: A case report with literature review. Anticancer Drugs 2002;13:327-330.
44. Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 1999;21:367-387.
45. Cowen D, Tardieu C, Schubert M, et al. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997;38(4):697-703.
46. Bensadoun RJ, Franquin JC, Ciasis C, et al. Low energy He-Ne laser in the prevention of radiation-induced mucositis: A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999;7:244-252.
47. Koukourakis M, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 2000;18: 2226-2233.
48. Bensadoun RJ, Magne N, Marcy PY, Demard F. Chemotherapy-and radiotherapy-induced mucositis in head and neck cancer patients: New trends in pathophysiology, prevention and treatment [review]. Eur Arch Otorhinolaryngol 2001;258(9):481-487.
49. Bensandoun RJ, Franquin JC, Ciais G, et al. Low-energy He-Nc laser in the prevention of radiation induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999;7(4): 244-252.